Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > J&J sitting on cash, wanting acquisitions
View:
Post by itntdf on Sep 04, 2023 7:32am

J&J sitting on cash, wanting acquisitions

While not an exact "fit" with Oncy, maybe a look at M&A activity for Q4 as we close out the year.

Johnson & Johnson plans to tap billions in proceeds from the recent split-off of its consumer-health business to fuel growth in pharmaceuticals and medical technology through capital allocation, which could include new acquisitions and investments in product offerings and robotics.


The New Brunswick, N.J.-based healthcare giant in May sold shares in Kenvue, which owns brands such as Band-Aid and Tylenol, through an initial public offering that netted J&J $13.2 billion in cash. 

J&J’s targets for acquisitions are businesses with scientific expertise and commercial capabilities that could benefit from J&J’s global reach, Wolk said. The company’s growth will continue to stem from a 50-50 split between organic, in-house development and expansion through acquisitions and partnerships, as it has historically, he said.

The company could acquire a mix of firms with already approved drugs and those with a late-stage pipeline that could launch a drug by the time a similar drug loses J&J exclusivity, said Damien Conover, director of healthcare equity research at financial-services firm Morningstar's research arm. 
Comment by Noteable on Sep 04, 2023 11:04am
J&J remains “really bullish” on Legend Biotech partnered CAR-T Carvykti for multiple myeloma patients “around the world,"  I see J&J after the CAR-T in solid tumors market, potentially making ONCY a direct fit. https://www.fiercepharma.com/financials/johnson-johnson-sticks-2025-projection-60-billion-pharma-sales-relying-eight-key-brands
Comment by Noteable on Sep 04, 2023 11:20am
 J&J expects its new multiple myeloma therapies will complement existing treatments rather than cannibalize each other’s sales.  https://www.biopharmadive.com/news/johnson-johnson-cancer-drug-sales-pharma-4q22/641071/
Comment by Buckhenry on Sep 04, 2023 8:42pm
I think canuckfan and unnoteable post continually to keep themselves pumped up. Their message has not changed in 4 years. Canuckfan's latest post is so full of ifs and buts and maybes.   He reminds me of the guy that said... you know how you can tell a politician is lying.... his lips are moving.  
Comment by Noteable on Sep 05, 2023 10:00am
No need to change the message when waiting on the rest to catch up.
Comment by Buckhenry on Sep 05, 2023 12:54pm
SOS.... different month and year and decade...but please be very patient...lol 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities